Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04805892 · ClinicalTrials.gov registry record · NA
Study Utilizing BIOZEK COVID-19 Antigen Rapid Test.
A NA study, sponsored by Mach-E B.V..
- Completed
- Registry status
- NA
- Development phase
- 84
- Enrollment target
NCT04805892: Completed NA study, sponsored by Mach-E B.V..
NCT04805892 is a NA study that has completed, run by Mach-E B.V.. The registered enrollment target is 84 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04805892, a NA study, has completed, sponsored by Mach-E B.V..
- COMPLETED
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
Study Summary
This is a research study to evaluate the Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test on samples collected by a healthcare professional versus self-collection; and to perform analysis to compare results. In addition, to obtain RT-PCR test results, performed prior to enrollment, and compare all three results.
Primary Outcome
The Biozek Antigen Rapid Tests performed by the trained study personnel on the samples collected by the trained study personnel. Sensitivity was calculated using (TP/TP+FN)\*100% formula. Specificity was calculated using (TN/TN+FP)\*100% formula.
Interventions
- DIAGNOSTIC_TEST BIOZEK COVID-19 Antigen Rapid Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2022-02-23 |
| Phase | NA |
What the finished NCT04805892 record still lists
NCT04805892 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which BIOZEK COVID-19 Antigen Rapid Test is the first listed.
NCT04805892 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04805892 about?
NCT04805892 is a clinical study titled "Study Utilizing BIOZEK COVID-19 Antigen Rapid Test.". This is a research study to evaluate the Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test on samples collected by a healthcare professional versus self-collection; and to perform analysis to compare results. In addition, to obtain RT-PCR test results, performed prior to enrollment, ...
What is the current status of trial NCT04805892?
This trial is currently completed. It is a NA study. The enrollment target is 84 participants. The study started on 2021-03-17. Estimated completion is 2022-02-23.
What interventions are being tested in trial NCT04805892?
The interventions under investigation include: BIOZEK COVID-19 Antigen Rapid Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04805892?
This trial is sponsored by Mach-E B.V., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04805892's enrollment target sits among peer trials
84 983rd of 2000 higher than 1,011 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI